Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Knight Therapeutics Inc T.GUD

Alternate Symbol(s):  KHTRF

Knight Therapeutics Inc. is a specialty pharmaceutical company. The Company’s principal business activity is developing, acquiring, in-licensing, out-licensing, manufacturing, marketing and distributing pharmaceutical products in Canada, Latin America and select international markets. It finances other life sciences companies and secures product distribution rights for Canada and select... see more

TSX:GUD - Post Discussion

Knight Therapeutics Inc > To clarify ...
View:
Post by MrMugsy on Apr 23, 2022 12:54pm

To clarify ...

I'm saying that raising the cash wasn't a mistake.

What they intended to do with the investment funds didn't pan out as expected - failure can be debated at different levels here.

-------------------

With the cash ... the plan is coming together ... but it won't be quick ...

First, it was to cash up as Goodman's name allowed for it.
2nd, it was to build ROW and Israel was supposed to already be a part of ROW - oh well.
3rd, it's about optimization and growing ROW cashflow.
Then, likely more partnerships inside/outside the Americas - using the shelf prospectus to grow this - but don't expect to go to market under $12 per share - they will likely wait it out as that is this team's nature.
Then maybe a Big Pharma to take a position in our company with an option to acquire.
Then we likely sell to the partner -OR- GUD and the partner sell to a 3rd party Big Pharma based on valuations and who's willing to pay up.

Just one way to look at how it evolves - not a quick process indeed !
Selling the company at 5 to 6x sales?  Sure!
That's way down the road when they've exhausted all profitable angles of ROW development.
Comment by Snowballgrowth on Apr 24, 2022 7:42am
Yes They raised too much cash at the wrong time, during year one. Bad for the company and worse for the investors. Many paid $ 10 back then. The other huge mistake had been to invest in Israel with this partner. The third biggest mistake had been the idea to invest in funds without to be sure to get products rights.  Those mistakes explain why they are few years behind the roadmap and even ...more  
Comment by EbbFlow88 on Apr 24, 2022 8:44am
Companies should raise money if it's on favorable terms to them. At 10$ it was clearly favorable. Not so for those who bought then but over time it may prove to still be a good investment (I believe it will, obviously).  I think everyone will agree that the Israel investment was a mistake. No arguments there. The funds are pretty neutral in my book. Yes, not much has come in terms of ...more  
Comment by EbbFlow88 on Apr 24, 2022 8:51am
Regardless, we all give our opinions at the end of the day its the results and shareprice that matter and why we're all here. For now, I'm optimistic about GUD's future. That may change as more results come in. It's up to the team to perform and I sincerely hope they do for all of us.  Q1 coming out in a couple of weeks. Hope we continue to trend in the right direction. Good ...more  
Comment by Snowballgrowth on Apr 24, 2022 9:01am
These 3 mistakes had been huge and many investors didn't like the fact than many hundred million had been dead money for a so long period.  The mistakes aren't only about cost opportunity and the fact than the return on capital had been so low. Even the good execution on the field can turn negative with bad capital allocation or with products price increase.  Again I am a ...more  
Comment by Chianchin on Apr 25, 2022 4:19am
Raising money with a PP to leave that cash mostly idlle, than over pay GBT and afterwords stiff investors for using that money for a buy back is the worst coporate action any company can take. Bay street has a very very long unforgiven memory on that 
Comment by MrMugsy on Apr 25, 2022 10:15am
Don't think you'll have to worry about Bay Street or Wall Street. When they come to the party it will be a whole new group of investors who are looking for the next level of operational success. To this point - it's been 270 diehard builders (and a few thousand regular average joes who joined the builders) who are absolutely sold on building it better ... better - stronger - faster . ...more  
Comment by GoldenInvestor on Apr 25, 2022 10:52am
& how many of the strategic original owners have left so far?  I say none.   Many like me, have been increasing our ownership along the way.   looking forward to operational growth, which is already happening and looking to buy more. I appreciate the critics as it makes me revisit my investment thesis and just confirm it, over and over again!! GUD times ahead! GI
Comment by MrMugsy on Apr 24, 2022 1:45pm
Yes - we all have our opinions and that's all they are - not about changing people's minds. I agree that you go to market when the price is high and you buy back shares when the price is low.  That's why you likely won't see this crew going to market until the price is above 10 - never seen them do it but ... I guess it depends if something comes available that is too good of ...more  
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities